<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838316</url>
  </required_header>
  <id_info>
    <org_study_id>801019</org_study_id>
    <secondary_id>801019-1</secondary_id>
    <nct_id>NCT02838316</nct_id>
  </id_info>
  <brief_title>Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia</brief_title>
  <official_title>Muscle Cell Mediated Therapy for Tongue Dysphagia: An Investigation of Cook MyoSite Autologous Muscle Derived Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Belafsky, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cook MyoSite</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety of Autologous Muscle Derived&#xD;
      Cells for Gastro-Intestinal Repair (AMDC-GIR) during the 12 months following treatment of&#xD;
      tongue dysphagia in male and female patients who have undergone surgery and/or chemo- and/or&#xD;
      radiotherapy for squamous cell cancer of the oropharynx.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This preliminary, prospective, dose escalating clinical study will evaluate the safety and&#xD;
      potential efficacy of Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)&#xD;
      for the treatment of tongue dysphagia (TD) that develops following treatment for head and&#xD;
      neck cancer.&#xD;
&#xD;
      Surgery, chemo- and radiotherapy can induce significant TD resulting in long-term TD.&#xD;
      Therefore, augmenting tongue muscle function may be beneficial to patients. Autologous muscle&#xD;
      cell therapy, which involves isolation of cells from skeletal muscle biopsies, ex vivo&#xD;
      expansion, and subsequent injection into the tongue, may serve as a potential durable&#xD;
      therapy. In animal studies, muscle derived cells have successfully integrated within tissue&#xD;
      to improve tongue strength and function. Intramuscular injection of AMDC-GIR is expected to&#xD;
      produce localized tissue changes near the injection site and is not expected to produce a&#xD;
      systemic effect.&#xD;
&#xD;
      Patients will receive a single treatment intramuscular injection of 1 of 2 doses of AMDC-GIR.&#xD;
      Patients will have quantitative and qualitative measures of dysphagia assessed before&#xD;
      treatment and at various times after treatment.&#xD;
&#xD;
      The study will treat up to 20 patients at 1 clinical site. Enrollment is expected to be&#xD;
      completed within 2 years of initiating the study. Patients will be followed for 24 months&#xD;
      post-treatment. The first 3 patients at each dose must reach 1-month follow-up before&#xD;
      subsequent patients can be treated.&#xD;
&#xD;
      Male and female patients at least 18 years of age who have undergone surgery and/or chemo-&#xD;
      and or radiotherapy for primary treatment of oropharyngeal squamous cell cancer and who&#xD;
      present with symptoms and findings of TD will be eligible for participation. Eligible&#xD;
      patients will have muscle tissue harvested using a needle biopsy technique during an&#xD;
      outpatient procedure. The harvested muscle tissue will be transported to the manufacturer for&#xD;
      cell processing. The muscle derived cells (MDC) will be isolated and expanded in culture over&#xD;
      several weeks.&#xD;
&#xD;
      After reaching the desired concentration, the isolated and expanded AMDC-GIR will be frozen&#xD;
      and shipped back to the investigating physician. The physician will thaw the AMDC-GIR and&#xD;
      dilute the sample with an approximately equal volume of physiological saline. Under direct&#xD;
      vision, the resulting suspension will be injected into the patient's tongue in a brief&#xD;
      outpatient procedure.&#xD;
&#xD;
      Patients will be assessed for improvement in TD symptoms at 3 months, 6 months, 12 months and&#xD;
      24 months following treatment. Adverse events will be assessed at those visits, as well as&#xD;
      during follow-up calls at 1-2 days, 1 week, 15 months, 18 months and 21 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase I open label clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study product-related Serious Adverse Events (SAEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate the safety of AMDC-GIR following treatment of tongue dysphagia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study product-related, biopsy procedure-related, and injection procedure-related adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Safety will be determined by the frequency and severity of adverse events related to study procedures and study product</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penetration-Aspiration scale rating from swallowing fluoroscopy</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy of AMDC-GIR in the improvement of objective fluoroscopic swallowing parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharyngeal Constriction Ratio measurement from swallowing fluoroscopy</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy of AMDC-GIR in the improvement of objective fluoroscopic swallowing parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper Esophageal Sphincter opening measurement from swallowing fluoroscopy</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy of AMDC-GIR in the improvement of objective fluoroscopic swallowing parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharyngeal transit time measurement from swallowing fluoroscopy</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy of AMDC-GIR in the improvement of objective fluoroscopic swallowing parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak pharyngeal pressure measurement from high-resolution manometry</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy of AMDC-GIR in the improvement of objective manometric swallowing parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior tongue pressure measurement from Iowa Oral Performance Instrument (IOPI)</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy of AMDC-GIR in the improvement of objective Anterior Tongue Pressure Measurement (IOPI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported dysphagia symptoms based on Eating Assessment Tool- EAT10 score</measure>
    <time_frame>24 months</time_frame>
    <description>Effect of AMDC-GIR on patient-reported dysphagia symptoms [Eating Assessment Tool- EAT10]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life based on SF-12 survey score</measure>
    <time_frame>24 months</time_frame>
    <description>Effect of AMDC-GIR on patient-reported dysphagia symptoms quality of life (QOL) [SF-12]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported voice symptoms based on Voice Handicap Index - VHI10 score</measure>
    <time_frame>24 months</time_frame>
    <description>Effect of AMDC-GIR on patient-reported dysphagia symptoms and voice symptoms [Voice Handicap Index - VHI10]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Oropharyngeal Dysphagia</condition>
  <arm_group>
    <arm_group_label>150 x 106 dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects will be receiving a dosage of 150 x 106 AMDC-GIR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 x 106 dosage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 subjects will be receiving a dosage of 300 x 106 AMDC-GIR</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)</intervention_name>
    <description>Autologous muscle derived stem cells</description>
    <arm_group_label>150 x 106 dosage</arm_group_label>
    <arm_group_label>300 x 106 dosage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or Female, at least 18 years old, with primary symptoms of TD following surgery&#xD;
             and/or chemo- and/or radiotherapy for treatment of squamous cell carcinoma for&#xD;
             oropharyngeal cancer. Treatment must be completed at least 24 months prior to&#xD;
             enrollment, with TD and disease-free status confirmed by medical history and clinical&#xD;
             symptoms, including a focused head and neck examination evaluation, swallowing&#xD;
             fluoroscopy, and high resolution pharyngeal manometry.&#xD;
&#xD;
          2. TD severity should be moderate as defined by a Functional Oral Intake Scale (FOIS,&#xD;
             provided in Appendix C). Individuals must have a FOIS of 3 or better.&#xD;
&#xD;
          3. Patient has failed to achieve acceptable resolution of symptoms following conservative&#xD;
             therapies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient History-based Criteria:&#xD;
&#xD;
          1. Simultaneously participating in another investigational drug or device study or has&#xD;
             completed the follow-up phase for the primary endpoint of any previous study less than&#xD;
             30 days prior to the first evaluation in this study.&#xD;
&#xD;
          2. Previously treated with an investigational device, drug, or procedure for TD within 6&#xD;
             months prior to signing consent.&#xD;
&#xD;
          3. Has ever been treated with a cell therapy for TD.&#xD;
&#xD;
          4. Symptoms of aspiration pneumonia prior to enrollment.&#xD;
&#xD;
          5. TD of neurogenic etiology or uncorrected congenital abnormality leading to TD.&#xD;
&#xD;
          6. Neuromuscular disorder (e.g., Parkinson's disease, muscular dystrophy, multiple&#xD;
             sclerosis) that could lead to TD.&#xD;
&#xD;
          7. Moderate or severe fibrosis at likely injection site.&#xD;
&#xD;
          8. Morbidly obese (BMI â‰¥ 35).&#xD;
&#xD;
          9. Uncontrolled diabetes.&#xD;
&#xD;
         10. Compromised immune system due to disease state, chronic corticosteroid use, or other&#xD;
             immunosuppressive therapy.&#xD;
&#xD;
         11. Medical condition or disorder that may limit life expectancy or that may cause&#xD;
             clinical investigation plan (CIP) deviations (e.g., unable to perform self-evaluations&#xD;
             or accurately report medical history, symptoms, or data).&#xD;
&#xD;
         12. History of bleeding diathesis or uncorrectable coagulopathy.&#xD;
&#xD;
         13. Known allergy or hypersensitivity to bovine proteins or allergens, gentamicin sulfate,&#xD;
             or ampicillin that medically warrants exclusion as determined by the physician.&#xD;
&#xD;
         14. Any non-skin cancer that has necessitated treatment within the past 24 months.&#xD;
&#xD;
        Patient's Current Status-based Criteria:&#xD;
&#xD;
          1. Evidence or known high risk of recurrent or persistent cancer as determined by the&#xD;
             physician during screening.&#xD;
&#xD;
          2. Tests positive for Hepatitis B (required tests: Hepatitis B Surface Antigen [HBsAg]&#xD;
             and Anti-Hepatitis B Core Antibody [Anti-HBc]), Hepatitis C (required test: Hepatitis&#xD;
             C Antibody [Anti-HCV]), HIV (required tests: HIV Type 1 and 2 Antibodies [Anti-HIV-1,&#xD;
             2]), and/or Syphilis.&#xD;
&#xD;
             a. Tests performed by certified/authorized testing laboratory using licensed/approved&#xD;
             tests and performed on blood samples collected within 30 days prior to muscle tissue&#xD;
             procurement.&#xD;
&#xD;
          3. Cannot, or is not willing to, maintain the current treatment regimen for existing&#xD;
             conservative therapy (e.g., swallowing therapy).&#xD;
&#xD;
          4. Requires prophylactic antibiotics for chronic infections, or has required 2 or more&#xD;
             courses of antibiotics for infections in the 2 months prior to signing consent.&#xD;
&#xD;
          5. Any condition, including current infection, which could lead to significant&#xD;
             postoperative complications.&#xD;
&#xD;
          6. Refuses to provide written informed consent.&#xD;
&#xD;
          7. Not available for, or willing to comply, with the baseline and follow-up evaluations&#xD;
             as required by the CIP.&#xD;
&#xD;
          8. Pregnant, lactating, or plans to become pregnant during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Belafsky, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Davis, Department of Otolaryngology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maggie Kuhn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California Davis, Department of Otolaryngology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nogah Nativ, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California Davis, Department of Otolaryngology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nogah Nativ, PhD</last_name>
    <phone>9167348763</phone>
    <email>nhnativ@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Belafsky, MD, PhD</last_name>
    <phone>9167348763</phone>
    <phone_ext>1</phone_ext>
    <email>pcbelafsky@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Medical Center, Department of Otolaryngology, Head and Neck Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nogah Nativ, PhD</last_name>
      <email>nhnativ@ucdavis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Peter Belafsky, MD</investigator_full_name>
    <investigator_title>Professor and Director of Voice and Swallowing Center,UC Davis Health System-Department of Otolaryngology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deglutition Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

